LYMPHOMAS

Novel targets continue to emerge through clinical trials in peripheral T0cell lymphoma, in particular EZH 1 and EZH 2 inhibitors, which have strong single-agent efficacy.

Sattva S. Neelapu, MD will discuss chimeric antigen receptor T-cell therapy will in lymphoma iduring a session at the SOHO 2022 Annual Meeting.

Novel therapies for cutaneous T-cell lymphoma novel therapies for this patient population are helping to create straightforward management strategies.

A SOHO 2022 presentation by Jason Westin, MD will focus on t on 2 main categories of novel agents that manipulate the immune system to better target aggressive lymphomas.

In an interview with Targeted Oncology, Matthew Matasar, MD, discusses background information on the ongoing VITALIZE trial of maveropepimut-S in patients with diffuse large B-cell lymphoma.

New studies have shown promise for updated standards of care in patients with lymphoma.

Investigators for a phase 2 study of linperlisib began dosing its first patient with relapsed/refractory peripheral T/NK cell lymphoma.

Data presented at ESMO 2022 showed GSK3326595, aPRMT5 inhibitor, to display efficacy and safety signals consistent with those that were previously reported in advanced solid tumors.

In a study, a correlation between frailty status and death at 1 year was identified in patients with diffuse large B-cell lymphoma.

The TakeAim Lymphoma study will continue to evaluate emavusertib with or without ibrutinib in patients with various types of lymphoma after a 4 1/2-month partial clinical hold placed by the FDA.

Ian Flinn, MD, PhD, describes some of the important unmet needs of DLBCL, particularly in R/R DLBCL, and shares his hopes for the future of treatment.

An oncologist shares which treatment regimen he would recommend next for this patient with DLBCL who experienced two disease relapses and reflects on how CD19- and CD79b-targeted therapies have impacted patient outcomes in the field.

Dr Ian Flinn explains the available treatment options for patients with DLBCL who experience 2 or more relapses, and the situations in which he would use each regimen.

An expert provides his perspective on the first- and second-line treatment approaches in the patient case and comments on the patient’s likely prognosis.

Ian Flinn, MD, PhD, presents the case of a 68-year-old man with diffuse large B-cell lymphoma (DLBCL) and 2 relapses after complete disease remission.

A high overall response rate was demonstrated with epcoritamab treatment in patients with diffuse large B-cell lymphoma, according to results from the phase 1/2 EPCORE NHL-2 trial.

By April 2023, the FDA plans have a decision on the approval application for polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone as an option for treatment-naïve diffuse large B-cell lymphoma.

Closing out the program, Dr Gilles Salles highlights currently unmet needs in DLBCL and investigational treatments he finds exciting.

Dr Gilles Salles shares his opinion on the presented case’s treatment decision and the regimen he would have selected for the patient.

Gilles Salles, MD, PhD, explains data on the adverse events seen with the pola-BR regimen in R/R DLBCL during the GO29365 clinical trial.

A review of population, dosing, and efficacy data from the GO29365 clinical trial investigating the combination of polatuzumab, bendamustine, and rituximab (pola-BR) for R/R DLBCL.

Dr Salles provides an overview of the available third-line treatment options for patients with R/R DLBCL who are ineligible for or do not wish to receive autologous stem cell transplant or CAR T-cell therapy.

An oncologist describes the typical major challenges of managing patients with R/R DLBCL and the incidence of relapsed or refractory disease.

Gilles Salles, MD, PhD, presents the case of a 51-year-old woman with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

Findings from a phase 1 study concluded zandelisib given to patients with relapsed/refractory B-cell malignancies at 60 mg once daily in an intermittent dosing schedule reflected in a positive safety profile.